BioNTech
Spain touts mass vaccine plan, sees light at tunnel’s end
After months of turmoil and over 42,000 deaths, Spain appeared to see light at the end of the tunnel Friday, announcing ambitious plans to vaccinate much of the population by mid-2021. The post Spain touts mass vaccine plan, sees light at tunnel’s end appeared first on TODAY. You Deserve to Make Money Even When you are looking for Dates Online. So we reimagined what a dating should be. It begins with giving you back power. Get to meet Beautiful people, chat and make money in the process. Earn rewards by chatting, sharing photos, blogging and help give users back their fair share of Internet revenue.
Coronavirus vaccine eclipses US elections as economic game-changer
It started on Monday when Pfizer announced that the COVID-19 vaccine it is developing with Germany’s BioNTech proved 90 percent effective in a late-stage trial. The post Coronavirus vaccine eclipses US elections as economic game-changer appeared first on TODAY. You Deserve to Make Money Even When you are looking for Dates Online. So we reimagined what a dating should be. It begins with giving you back power. Get to meet Beautiful people, chat and make money in the process. Earn rewards by chatting, sharing photos, blogging and help give users back their fair share of Internet revenue.
Europe to pay less than US for Pfizer COVID-19 vaccine
The European Union has struck a deal to initially pay less for Pfizer’s COVID-19 vaccine candidate than the United States, an EU official told Reuters News Agency as the bloc announced on Wednesday it had secured an agreement for up to 300 million doses. The experimental drug, developed in conjunction with Germany’s BioNTech, is the frontrunner in a global race to produce a vaccine, with interim data released on Monday showing it was more than 90 percent effective at protecting people from COVID-19 in a large-scale clinical trial. Under the EU deal, 27 European countries could buy 200 million doses, and have an option to buy another 100 million. The bloc will pay less than $19.50 per jab, a senior EU official involved in talks with vaccine makers told Reuters, adding that partly reflected ...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
